𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cerebral alterations in a MPTP-mouse model of Parkinson’s disease – an immunocytochemical study

✍ Scribed by Y. Muramatsu; R. Kurosaki; H. Watanabe; M. Michimata; M. Matsubara; Y. Imai; T. Araki

Publisher
Springer
Year
2003
Tongue
English
Weight
770 KB
Volume
110
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuroprotective effects of (±)-kavain in
Neuroprotective effects of (±)-kavain in the MPTP mouse model of Parkinson's disease
✍ Nicole Schmidt; Boris Ferger 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 2 views

This is the first study to investigate the potential protective effects of the lipophilic kavapyrone (+/-)-kavain in the experimental MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease (PD). Male C57BL/6 mice were treated with (+/-)-kavain (50, 100, or 200 mg/kg i.p.) o

Hexokinase II gene transfer protects aga
Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease
✍ Juan Carlos Corona; Alfredo Gimenez-Cassina; Filip Lim; Javier Díaz-Nido 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 407 KB

## Abstract A typical feature of Parkinson's disease is the progressive loss of dopaminergic neurons in the substantia nigra, in which inhibition of mitochondrial complex I activity may play an important role. Rotenone or 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) inhibit the mitochondrial